Latest research on Rosuvastatin

Rosuvastatin is an antilipemic agent that competitively inhibits hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase. HMG-CoA reducuase catalyzes the conversion of HMG-CoA to mevalonic acid, the rate-limiting step in cholesterol biosynthesis. Rosuvastatin belongs to a class of medications called statins and is used to reduce plasma cholesterol levels and prevent cardiovascular disease.

Latest findings

The available studies have also shown that the effectiveness of statin therapy, especially high-intensive regimens with Rosuvastatin 20–40 mg and Atorvastatin 40–80 mg, could be very high, and even in >90 % of patients we might achieve lipid goals [14]. [source, 2016]
Several factors can influence residual risk; this is associated with patients at very high risk with concomitant diseases and polypharmacy, and the problem of significant underuse of high doses of statins – in many European countries as well as in the United States Atorvastatin 80 mg or Rosuvastatin 40 mg is used in <5 % of dyslipidaemic patients [20–22]. [source, 2016]
These findings complement and extend the above-mentioned meta-analyses [24] as well as the results from the Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) trial [27], which reported that statins reduced death from any cause by 12 %. [source, 2016]
Other groups reported that Rosuvastatin improved survival of ADSCs after transplantation into infarcted hearts. [source, 2016]
Improved cardiac function and reduced fibrosis were observed in Rosuvastatin plus ADSC group. [source, 2016]
Bioluminescence imaging and histological staining in vivo revealed that Rosuvastatin (20 mg/kg per day for 28 days) enhanced the survival of engrafted ADSC approximately 1.3-fold compared to MSC alone. [source, 2016]
This was associated with the idea that Rosuvastatin increased Akt, ERK phosphorylation, promoted the subsequent FoxO3a phosphorylation and nuclear export, and decreased the proapoptotic proteins in ADSCs [119]. [source, 2016]
On the contrary, Rosuvastatin did not affect baseline leukocytes' count or the postprandial neutrophils' increase in CAD patients [44]. [source, 2016]
Rosuvastatin (AstraZeneca, Wilmington, DE) was dissolved in 30-μL polysorbate 80. [source, 2016]
The saline vehicle was prepared similarly without the addition of Rosuvastatin. [source, 2016]